FDA Approved 2025 Research (6)
6 papers in the FDA Approved 2025 topic, indexed by PF-Atlas from PubMed and global journals.
- Jascayd : a novel PDE4B inhibitor for idiopathic pulmonary fibrosis. · Annals of medicine and surgery (2012) · 2026
- Nerandomilast attenuates Pantoea agglomerans-induced hypersensitivity pneumonitis by regulating M1 macrophage polarization and fibroblast activation. · Respiratory research · 2026
- Precision Modulation of the PDE4 Pathway: The Emerging Role of Nerandomilast in Pulmonary Fibrosis. · The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2026
- [Management of Progressive Pulmonary Fibroses - 2025 Update]. · Deutsche medizinische Wochenschrift (1946) · 2026
- Nerandomilast Improves Bleomycin-Induced Systemic Sclerosis-Associated Interstitial Lung Disease in Mice by Regulating the TGF-β1 Pathway. · Inflammation · 2025
- Nerandomilast. · 2012
Medical disclaimer. Research listings are for information only and are not medical advice.